Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Scynexis Inc chart...

About the Company

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Exchange

NASDAQ

Website

http://www.scynexis.com/

$0M

Total Revenue

81

Employees

$53M

Market Capitalization

0.94

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SCYX News

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

8h ago, source:

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024Data analysis for the FURI ...

SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023

on MSN ago, source:

SCYX stock results show that SCYNEXIS missed analyst estimates for earnings per share but beat on revenue for the fourth ...

Scynexis files patent for treatment of fungal infections with enfumafungin derivative triterpenoids

2d ago, source: Pharmaceutical Technology

Discover Scynexis Inc.'s patent for enfumafungin derivative triterpenoid antifungal compounds targeting fungal infections in low pH environments. Learn about the innovative treatment options for yeast ...

Buy Recommendation for Astria Therapeutics Backed by Promising ALPHA-STAR Trial Results

2d ago, source:

Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on Astria Therapeutics (ATXS – Research Report), with a ...

NRx unveils plan to battle naked short selling in shares

on MSN ago, source:

NRx Pharmaceuticals (NRXP) stock jumped 9% in premarket trading Tuesday after the company unveiled a plan to combat naked ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...